Skip to main content

Table 3 Risk of DFR according to PT’s characteristics

From: Early persistence on therapy impacts drug-free remission: a case-control study in a cohort of Hispanic patients with recent-onset rheumatoid arthritis

  Model 1 Model 2 Model 3
HR (95% CI), p value
% of the patient follow-up PT 1.00 (0.98–1.02), 0.659 1.00 (0.98–1.02), 0.959  
Early PT 1.79 (0.59–5.46), 0.303 3.84 (1.13–13.07), 0.031 3.16 (1.14–8.77), 0.027
Baseline SF-36 physical component score 0.99 (0.96–1.02), 0.47   0.98 (0.96–1.01), 0.136
Cumulative (up to the first 2 years of follow-up) number of DMARDs/patient   0.19 (0.08–0.45), ≤ 0.001 0.12 (0.07–0.41), ≤ 0.001
  1. HR hazard ratio, CI confidence interval, PT persistence on therapy, SF-36 Short Form 36, DMARDs disease-modifying anti-rheumatic drugs